Aptevo Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aptevo Therapeutics generated cash of -$11,730,000, which is more than the previous year. Cash used in financing activities reached the amount of $5,998,000 last year. Net change in cash is therefore -$5,732,000.
Cash Flow
| 2014 | -47.00M | -48.8M | 99.4M |
|---|---|---|---|
| 2015 | -48.76M | -1.52M | 51.33M |
| 2016 | -36.86M | -47.39M | 89.29M |
| 2017 | -41.57M | 29.45M | 9.53M |
| 2018 | -51.42M | 72.79M | -787K |
| 2019 | -42.38M | 4.09M | 20.14M |
| 2020 | -29.31M | 28.03M | 23.87M |
| 2021 | -21.67M | -713K | 26.16M |
| 2022 | -21.02M | -29K | -2.61M |
| 2023 | -11.73M | 0 | 5.99M |
APVO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 22.63M | 46.30M | 42.53M | 19.94M | 38.08M | 17.49M | 9.67M | 4.63M | 3.59M | 0 |
Operating activities | ||||||||||
Net income | -17.41M | 8.02M | -28.45M | -17.75M | -40.44M | -53.68M | 6.97M | -112.41M | -59.31M | -51.11M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 567K | 901K | 1.14M | 1.40M | 2.23M | 2.39M | 3.12M | 3.36M | 2.90M | 2.02M |
Stock-based compensation expense | 2.19M | 1.80M | 1.64M | 1.25M | 1.59M | 2.14M | 4.88M | 3.80M | 1.10M | 1.07M |
| Deferred income tax benefit | 2.19M | 1.80M | 1.64M | 1.25M | 1.59M | 2.14M | 4.88M | 3.80M | 1.10M | 1.07M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 2.5M | 1.16M | -1.29M | -2.36M | -1.80M | -3.07M | -1.83M | 1.97M | 3.88M | -6.13M |
Inventories | 0 | -1.16M | 1.29M | -1.05M | -4.35M | -757K | -567K | 13.68M | -2.69M | 4.95M |
Accounts payable | 518K | -394K | -1.91M | -702K | -2.69M | 1.27M | 195K | 2.47M | -1.66M | 820K |
Cash generated by operating activities | -11.73M | -21.02M | -21.67M | -29.31M | -42.38M | -51.42M | -41.57M | -36.86M | -48.76M | -47.00M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -16.53M | -99.63M | -44.88M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -29K | -713K | -88K | -153K | -976K | -1.40M | -2.51M | -1.52M | -989K |
Acquisitions Net | 0 | 0 | 0 | 28.12M | 4.25M | 65K | 59.76M | 0 | 0 | -47.81M |
Cash generated by investing activities | 0 | -29K | -713K | 28.03M | 4.09M | 72.79M | 29.45M | -47.39M | -1.52M | -48.8M |
Financing activities | ||||||||||
Common Stock Issued | 6.42M | 6.93M | 11.43M | 21.25M | 20.34M | 623K | 442K | 18K | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -11K | 0 | -808K | -758K | 0 | 0 | 0 |
Repayments of term debt | -3.46M | -12.26M | -10.55M | -22.10M | -137K | -602K | 0 | -18.03M | 0 | 0 |
Cash used in financing activities | 5.99M | -2.61M | 26.16M | 23.87M | 20.14M | -787K | 9.53M | 89.29M | 51.33M | 99.4M |
Net Change In Cash | -5.73M | -23.66M | 3.76M | 22.58M | -18.13M | 20.58M | -2.58M | 5.03M | 1.04M | 3.59M |
Cash at end of period | 16.90M | 22.63M | 46.30M | 42.53M | 19.94M | 38.08M | 7.09M | 9.67M | 4.63M | 3.59M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |